Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review

Australian and New Zealand Journal of Psychiatry

Volumn 47, Issue 7, 2013, Pages 624-630

  Taylor, Mark ^a   Ng, Ka Ying Bonnie ^a  

^a ROYAL EDINBURGH HOSPITAL   (United Kingdom)

Author keywords

Early; First episode; Long acting antipsychotic injections; Schizophrenia

Indexed keywords

CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; RISPERIDONE;

CASE CONTROL STUDY; COHORT ANALYSIS; EMBASE; EXTRAPYRAMIDAL SYMPTOM; FOLLOW UP; HUMAN; INJECTION SITE PAIN; MEDLINE; METABOLIC DISORDER; MORTALITY; MOTOR DYSFUNCTION; OPEN STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOSIS; PSYCINFO; RECURRENCE RISK; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SYSTEMATIC REVIEW; WEIGHT GAIN; WHITE MATTER;

EARLY; FIRST EPISODE; LONG-ACTING ANTIPSYCHOTIC INJECTIONS; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; HUMANS; MEDICATION ADHERENCE; SCHIZOPHRENIA;

EID: 84883270994     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867412470010     Document Type: Review

References (36)

1. Andreasen NC, Carpenter WT Jr, Kane JM, et al. (2005) Remission in schizophrenia: Proposed criteria and rationale for consensus. American Journal of Psychiatry 162: 441-449.
2. Bartzokis G, Lu PH, Amar CP, et al. (2011) Long acting injection versus oral risperidone in first-episode schizophrenia: Differential impact on white matter myelination trajectory. Schizophrenia Research 132: 35-41.
3. Birchwood M, Todd P and Jackson C (1998) Early intervention in psychosis. The critical period hypothesis. British Journal of Psychiatry. Supplement 172: 53-59.
4. Chatterjee A, Chakos M, Koreen A, et al. (1995) Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. American Journal of Psychiatry 152: 1724-1729.
5. Coldham EL, Addington J and Addington D (2002) Medication adherence of individuals with a first episode of psychosis. Acta Psychiatrica Scandinavica 106: 286-290.
6. Davis JM, Matalon L, Watanabe MD, et al. (1994) Depot antipsychotic drugs. Place in therapy. Drugs 47: 741-773.
7. Emsley R, Medori R, Koen L, et al. (2008) Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: A preliminary study. Journal of Clinical Psychopharmacology 28: 210-213.
8. Glazer WM (2007) The depot paradox. Behavioral Healthcare 27: 44-46.
9. Haddad PM, Taylor M and Niaz OS (2009) First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: Systematic review of randomised controlled trials and observational studies. British Journal of Psychiatry. Supplement 52: S20-28.
10. Heres S, Reichhart T, Hamann J, et al. (2011) Psychiatrists' attitude to antipsychotic depot treatment in patients with first-episode schizophrenia. European Psychiatry 26: 297-301.
11. Hogarty GE, Schooler NR, Ulrich R, et al. (1979) Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Archives of General Psychiatry 36: 1283-1294.
12. Hor K and Taylor M (2010) Suicide and schizophrenia: A systematic review of rates and risk factors. Journal of Psychopharmacology 24: 81-90.
13. Johnson DA (2009) Historical perspective on antipsychotic long-acting injections. British Journal of Psychiatry. Supplement 52: S7-12.
14. Kane JM and Garcia-Ribera C (2009) Clinical guideline recommendations for antipsychotic long-acting injections. British Journal of Psychiatry. Supplement 52: S63-67.
15. Kane JM, Rifkin A, Quitkin F, et al. (1982) Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Archives of General Psychiatry 39: 70-73.
16. Keith SJ, Pani L, Nick B, et al. (2004) Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatric Services 55: 997-1005.
17. Keks NA, Ingham M, Khan A, et al. (2007) Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. British Journal of Psychiatry 191: 131-139.
18. Kim B, Lee SH, Choi TK, et al. (2008) Effectiveness of risperidone long-acting injection in first-episode schizophrenia: In naturalistic setting. Progress in Neuro-psychopharmacology and Biological Psychiatry 32: 1231-1235.
19. Lasser RA, Bossie CA, Zhu Y, et al. (2007) Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness. Annals of Clinical Psychiatry 19: 65-71.
20. Mackay K, Taylor M and Patel MX (2011) Medication adherence and patient choice in mental health. British Journal of Hospital Medicine 72: 6-7.
21. Moller HJ, Llorca PM, Sacchetti E, et al. (2005) Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. International Clinical Psychopharmacology 20: 121-130.
22. Napryeyenko O, Burba B, Martinez G, et al. (2010) Risperidone long-acting injectable in recent-onset schizophrenia examined with clinician and patient self-report measures. Journal of Clinical Psychopharmacology 30: 200-202.
23. National Institue of Clinical Excellence (NICE) (2009) NICE CG82. Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care. London: NICE.
24. Parellada E (2006) Clinical experience and management considerations with long-acting risperidone. Current Medical Research and Opinion 22: 241-255.
25. Parellada E, Andrezina R, Milanova V, et al. (2005) Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. Journal of Psychopharmacology 19: 5-14.
26. Patel MX, Taylor M and David AS (2009) Antipsychotic long-acting injections: Mind the gap. British Journal of Psychiatry. Supplement 52: S1-4.
27. Robinson DG, Woerner MG, Alvir JM, et al. (1999) Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry 156: 544-549.
28. Rosenheck RA, Krystal JH, Lew R, et al. (2011) Long-acting risperidone and oral antipsychotics in unstable schizophrenia. New England Journal of Medicine 364: 842-851.
29. Samele C, Lawton-Smith S, Warner L, et al. (2007) Patient choice in psychiatry. British Journal of Psychiatry 191: 1-2.
30. Shajahan P, Spence E, Taylor M, et al. (2010) Comparison of the effectiveness of depot antipsychotics in routine clinical practice. The Psychiatrist 34: 273-279.
31. Strassnig M, Miewald J, Keshavan M, et al. (2007) Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: One-year analysis. Schizophrenia Research 93: 90-98.
32. Taylor D (2009) Psychopharmacology and adverse effects of antipsychotic long-acting injections: A review. British Journal of Psychiatry. Supplement 52: S13-19.
33. Tiihonen J, Haukka J, Taylor M, et al. (2011) A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. American Journal of Psychiatry 168: 603-609.
34. Tiihonen J, Wahlbeck K, Lonnqvist J, et al. (2006) Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: Observational follow-up study. British Medical Journal 333: 224.
35. Weiden PJ, Buckley PF and Grody M (2007) Understanding and treating 'first-episode' schizophrenia. The Psychiatric Clinics of North America 30: 481-510.
36. Weiden PJ, Schooler NR, Weedon JC, et al. (2009) A randomised controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: Initial adherence outcome. Journal of Clinical Psychiatry 70: 1397-1406.